NCT07847892

Brief Summary

This study will follow adults who previously received gamgertamig in another clinical study to evaluate long-term safety and clinical outcomes.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
39mo left

Started Oct 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 29, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

September 29, 2026

Status Verified

September 1, 2026

Enrollment Period

3.2 years

First QC Date

September 23, 2026

Last Update Submit

September 23, 2026

Conditions

Autoimmune Cytopenias

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Adverse Events

    Incidence, severity, seriousness, and frequency of adverse events.

    From study entry through Week 52

Secondary Outcomes (1)

  • Anti-Drug Antibodies to Gamgertamig

    From study entry through Week 52

Study Arms (1)

Participants Previously Treated With Gamgertami

Participants who completed an eligible parent gamgertamig study

Other: Observational

Interventions

ObservationalOTHER

Prior treatment with gamgertamig in an eligible parent study. No gamgertamig is administered in this follow-up study.

Participants Previously Treated With Gamgertami

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults who completed treatment and continue to demonstrate a clinical response in an eligible parent gamgertamig study.

You may qualify if:

  • Completed the protocol-defined treatment regimen in an eligible parent gamgertamig study.
  • Achieved and continues to demonstrate a clinical response.
  • Able and willing to provide informed consent.

You may not qualify if:

  • Not applicable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Watchful Waiting

Intervention Hierarchy (Ancestors)

Outcome Assessment, Health CareOutcome and Process Assessment, Health CareQuality of Health CareHealth Services Administration

Central Study Contacts

Study Sponsor

CONTACT

415-429-4887clinicaltrials@lakefrontbio.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2026

First Posted

September 29, 2026

Study Start

October 1, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

September 29, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share